A novel method for predicting the budget impact of innovative medicines:validation study for oncolytics
Background High budget impact (BI) estimates of new drugs have led to decision-making challenges potentially resulting in restrictions in patient access. However, current BI predictions are rather inaccurate and short term. We therefore developed a new approach for BI prediction. Here, we describe the validation of our BI prediction approach using oncology drugs as a case study. Methods We used Dutch population-level data to estimate BI where BI is defined as list price multiplied by volume. We included drugs in the antineoplastic agents ATC category which the European Medicines Agency (EMA) c... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Geenen , J W , Belitser , S , Vreman , R A , van Bloois , M , Klungel , O H , Boersma , C & Hovels , A M 2020 , ' A novel method for predicting the budget impact of innovative medicines : validation study for oncolytics ' , European Journal of Health Economics , vol. 21 , no. 6 , pp. 845-853 . https://doi.org/10.1007/s10198-020-01176-x |
Schlagwörter: | Budget impact / Oncology / Medicines / Budget impact estimation / Prediction modeling / Validation study / COST-EFFECTIVENESS / DRUGS / REIMBURSEMENT / NETHERLANDS |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27211774 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/fd815f6c-82dd-4487-99d7-07fe297c7b94 |